Nkarta Q1 net loss $29.5M; cash $450M; NKX019 lupus dosing on track

Nkarta, Inc.

2024-Q1 EPS reported -$0.58

Cash, equivalents and investments of $450.0M at March 31, 2024, including $240.1M from March offering.
Net loss of $29.5M ($0.58 per share) for Q1 2024; R&D expense $25.2M, G&A $7.5M.
First patient dosing with NKX019 in lupus nephritis expected H1 2024; IND cleared 4Q2023.
Preliminary NKX019 compressed dosing data in NHL expected mid-2024; 4/4 re-treated patients achieved CR.
Cash runway expected to fund operations into late 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nkarta, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $29.5 million, or $0.58 per basic and diluted share, for the first quarter of 2024., EPS $0.58 per basic and diluted share.

Period: the first quarter ended March 31, 2024
Net income: Net loss was $29.5 million, or $0.58 per basic and diluted share, for the first quarter of 2024.
EPS: $0.58 per basic and diluted share
Result: reported results

Exact text from the filing

Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056870

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.